NICX.F Stock Overview
Nicox S.A. operates as an ophthalmology company in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nicox S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.44 |
| 52 Week High | €0.44 |
| 52 Week Low | €0.44 |
| Beta | 0.89 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -30.84% |
| 3 Year Change | -91.65% |
| 5 Year Change | -93.33% |
| Change since IPO | -93.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| NICX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | -1.7% |
| 1Y | -30.8% | -0.2% | 22.4% |
Return vs Industry: NICX.F underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: NICX.F underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| NICX.F volatility | |
|---|---|
| NICX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NICX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NICX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 28 | Gavin Spencer | www.nicox.com |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. Fundamentals Summary
| NICX.F fundamental statistics | |
|---|---|
| Market cap | US$21.59m |
| Earnings (TTM) | -US$18.83m |
| Revenue (TTM) | US$3.88m |
5.6x
P/S Ratio-1.1x
P/E RatioIs NICX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NICX.F income statement (TTM) | |
|---|---|
| Revenue | €3.57m |
| Cost of Revenue | €16.90m |
| Gross Profit | -€13.33m |
| Other Expenses | €4.03m |
| Earnings | -€17.36m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | -372.97% |
| Net Profit Margin | -485.70% |
| Debt/Equity Ratio | 44.8% |
How did NICX.F perform over the long term?
See historical performance and comparison